<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="342dd6fc-b2d4-4d8c-e063-6294a90aaf72"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Maxidex 
 <sup>Â®</sup>
      <br/>
(dexamethasone ophthalmic suspension) 0.1%
 <br/>
Sterile
</title>
   <effectiveTime value="20250502"/>
   <setId root="603f0bac-16b8-42f5-985e-fb0d73ee284d"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="002147023"/>
            <name>Novartis Pharmaceuticals Corporation</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="002147023"/>
                  <name>Novartis Pharmaceuticals Corporation</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="342e3b35-0ab1-efb7-e063-6394a90ad910"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250502"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0078-0925" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Maxidex</name>
                        <formCode code="C60995" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUSPENSION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>dexamethasone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="GR686LBA74" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7S5I7G3JQL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXAMETHASONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7S5I7G3JQL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXAMETHASONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0078-0925-25" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20220705"/>
                                    <high value="20250930"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA013422" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="19660515"/>
                              <high value="20250930"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="342dd6fc-b2d5-4d8c-e063-6294a90aaf72"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>MAXIDEX (dexamethasone ophthalmic suspension) 0.1% is an adrenocortical steroid prepared as a sterile topical ophthalmic suspension. The active ingredient is represented by the chemical structure:</paragraph>
                  <renderMultiMedia referencedObject="MM0000001"/>
                  <paragraph>Chemical name: Pregna-1,4-diene-3,20-dione,9-fluoro-11,17,21-trihydroxy-16-methyl-,(11Î²,16Î±)-.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Each mL of MAXIDEX (dexamethasone ophthalmic suspension) 0.1% contains: Active:</content>dexamethasone 0.1%.
 
  <content styleCode="bold">Preservative:</content>benzalkonium chloride 0.01%.
 
  <content styleCode="bold">Vehicle:</content>hypromellose 0.5%.
 
  <content styleCode="bold">Inactives:</content>citric acid and/or sodium hydroxide (to adjust pH), dibasic sodium phosphate, edetate disodium, polysorbate 80, purified water, and sodium chloride.

 </paragraph>
               </text>
               <effectiveTime value="20220705"/>
               <component>
                  <observationMedia ID="MM0000001">
                     <text>chemical</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="chemical.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="342dd6fc-b2d6-4d8c-e063-6294a90aaf72"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Dexamethasone suppresses the inflammatory response to a variety of agents and it probably delays or slows healing.</paragraph>
               </text>
               <effectiveTime value="20220705"/>
            </section>
         </component>
         <component>
            <section>
               <id root="342dd6fc-b2d7-4d8c-e063-6294a90aaf72"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.</paragraph>
               </text>
               <effectiveTime value="20220705"/>
            </section>
         </component>
         <component>
            <section>
               <id root="342dd6fc-b2d8-4d8c-e063-6294a90aaf72"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Contraindicated in acute, untreated bacterial infections; mycobacterial ocular infections; epithelial herpes simplex (dendritic keratitis); vaccinia, varicella, and most other viral diseases of the cornea and conjunctiva; fungal disease of ocular structures; and in those persons who have shown hypersensitivity to any component of this preparation.</paragraph>
               </text>
               <effectiveTime value="20220705"/>
            </section>
         </component>
         <component>
            <section>
               <id root="342dd6fc-b2d9-4d8c-e063-6294a90aaf72"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>Prolonged use may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions or parasitic infections of the eye, corticosteroids may mask infection or enhance existing infection. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids. If these products are used for 10 days or longer, intraocular pressure (IOP) should be routinely monitored even though it may be difficult in children and uncooperative patients.</paragraph>
                  <paragraph>Employment of corticosteroid medication in the treatment of herpes simplex other than epithelial herpes simplex keratitis, in which it is contraindicated, requires great caution; periodic slit-lamp microscopy is essential.</paragraph>
               </text>
               <effectiveTime value="20220705"/>
            </section>
         </component>
         <component>
            <section>
               <id root="342dd6fc-b2da-4d8c-e063-6294a90aaf72"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20220705"/>
               <component>
                  <section>
                     <id root="342dd6fc-b2db-4d8c-e063-6294a90aaf72"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>FOR TOPICAL OPHTHALMIC USE. The possibility of persistent fungal infections of the cornea should be considered after prolonged corticosteroid dosing.</paragraph>
                        <paragraph>The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.</paragraph>
                     </text>
                     <effectiveTime value="20220705"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="342dd6fc-b2dc-4d8c-e063-6294a90aaf72"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>Do not touch dropper tip to any surface, as this may contaminate the contents. The preservative in MAXIDEX (dexamethasone ophthalmic suspension) 0.1%, benzalkonium chloride, may be absorbed by soft contact lenses. MAXIDEX (dexamethasone ophthalmic suspension) 0.1% should not be administered while wearing soft contact lenses.</paragraph>
                     </text>
                     <effectiveTime value="20220705"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="342dd6fc-b2dd-4d8c-e063-6294a90aaf72"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of MAXIDEX (dexamethasone ophthalmic suspension) 0.1%.</paragraph>
                     </text>
                     <effectiveTime value="20220705"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="342dd6fc-b2de-4d8c-e063-6294a90aaf72"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <text>
                        <paragraph>Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application in multiples of the therapeutic dose. In the mouse, corticosteroids produce fetal resorptions and a specific abnormality, cleft palate. In the rabbit, corticosteroids have produced fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc.</paragraph>
                        <paragraph>MAXIDEX (dexamethasone ophthalmic suspension) 0.1% should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the embryo or fetus. There are no adequate or well-controlled studies in pregnant women. However, prolonged or repeated corticoid use during pregnancy has been associated with an increased risk of intra-uterine growth retardation. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of hypoadrenalism.</paragraph>
                     </text>
                     <effectiveTime value="20220705"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="342dd6fc-b2df-4d8c-e063-6294a90aaf72"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when MAXIDEX (dexamethasone ophthalmic suspension) 0.1% is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20220705"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="342dd6fc-b2e0-4d8c-e063-6294a90aaf72"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of MAXIDEX have been established in the pediatric patients. Use of MAXIDEX in all pediatric age groups is supported by evidence from adequate and well-controlled studies of MAXIDEX in adults with safety data from additional adequate and well-controlled trials in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20220705"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="342dd6fc-b2e1-4d8c-e063-6294a90aaf72"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20220705"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="342dd6fc-b2e2-4d8c-e063-6294a90aaf72"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Glaucoma with optic nerve damage, visual acuity and field defects; cataract formation; secondary ocular infection following suppression of host response; and perforation of the globe may occur.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Clinical Studies Experience</content>
                  </paragraph>
                  <paragraph>In clinical studies with MAXIDEX, the most frequently reports adverse reactions were ocular discomfort occurring in approximately 10% of the patients and eye irritation occurring in approximately 1% of the patients. All other adverse reactions from these studies occurred with a frequency less than 1%, including keratitis, conjunctivitis, dry eye, photophobia, blurred vision, eye pruritis, foreign body sensation, increased lacrimation, abnormal ocular sensation, eyelid margin crusting, and ocular hyperemia.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Postmarketing Experience</content>
                  </paragraph>
                  <paragraph>Additional adverse reactions identified from post-marketing use include corneal erosion, dizziness, eye pain, eyelid ptosis, headache, hypersensitivity reactions, and mydriasis. Frequencies cannot be estimated from the available data.</paragraph>
                  <paragraph>The following additional adverse reactions have been reported with dexamethasone use:</paragraph>
                  <paragraph>Cushingâs syndrome and adrenal suppression may occur after use of dexamethasone in excess of the listed dosing instructions in predisposed patients, including children and patients treated with CYP3A4 inhibitors.</paragraph>
               </text>
               <effectiveTime value="20220705"/>
            </section>
         </component>
         <component>
            <section>
               <id root="342dd6fc-b2e3-4d8c-e063-6294a90aaf72"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>SHAKE WELL BEFORE USING. One or two drops topically in the conjunctival sac(s). In severe disease, drops may be used hourly, being tapered to discontinuation as the inflammation subsides. In mild disease, drops may be used up to four to six times daily.</paragraph>
                  <paragraph>Not more than one bottle should be prescribed initially, and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS above.</paragraph>
               </text>
               <effectiveTime value="20220705"/>
            </section>
         </component>
         <component>
            <section>
               <id root="342dd6fc-b2e4-4d8c-e063-6294a90aaf72"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>MAXIDEX
 
  <sup>Â®</sup>(dexamethasone ophthalmic suspension) 0.1% in plastic dispensers:

 </paragraph>
                  <paragraph>5 mL NDC 0078-0925-25</paragraph>
                  <paragraph>
                     <content styleCode="bold">STORAGE:</content>Store upright at 8Â°C to 27Â°C (46Â°F to 80Â°F).

 </paragraph>
                  <paragraph>After opening, MAXIDEX can be used until the expiration date on the bottle.</paragraph>
                  <paragraph>Â© Novartis</paragraph>
                  <paragraph>Distributed by: 
  <br/>  Novartis Pharmaceuticals Corporation 
  <br/>  East Hanover, New Jersey 07936
 </paragraph>
                  <paragraph>Revised: January 2022</paragraph>
                  <paragraph>T2022-01</paragraph>
               </text>
               <effectiveTime value="20220705"/>
            </section>
         </component>
         <component>
            <section>
               <id root="342dd6fc-b2e5-4d8c-e063-6294a90aaf72"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 0078-0925-25</paragraph>
                  <paragraph>MAXIDEX
 
  <sup>Â®</sup>
                  </paragraph>
                  <paragraph>(dexamethasone ophthalmic suspension) 0.1%</paragraph>
                  <paragraph>5 mL</paragraph>
                  <paragraph>Sterile</paragraph>
                  <paragraph>NOVARTIS</paragraph>
                  <renderMultiMedia referencedObject="MM0000002"/>
               </text>
               <effectiveTime value="20220705"/>
               <component>
                  <observationMedia ID="MM0000002">
                     <text>PRINCIPAL DISPLAY PANEL
							0078-0925-25
							MAXIDEXÂ® (dexamethasone ophthalmic suspension) 0.1%
							5 mL
							Sterile
							NOVARTIS</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>